Dr. Michael Johnson

    FDA Approves Gene Therapy to Treat Patients with Rare Form of Inherited Vision Loss

    5/22/2018 12:00:00 AM

    Healthy Living – May 22, 2018
    Michael Johnson, MD – Eastern Maine Medical Center
    The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is the first directly administered gene therapy approved in the U.S. that targets a disease caused by mutations in a specific gene.

    Luxturna is approved for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy that leads to vision loss and may cause complete blindness in certain patients.
    Hereditary retinal dystrophies are a broad group of genetic retinal disorders that are associated with progressive visual dysfunction and are caused by mutations in any one of more than 220 different genes. Biallelic RPE65 mutation-associated retinal dystrophy affects approximately 1,000 to 2,000 patients in the U.S. Biallelic mutation carriers have a mutation (not necessarily the same mutation) in both copies of a particular gene (a paternal and a maternal mutation). The RPE65 gene provides instructions for making an enzyme (a protein that facilitates chemical reactions) that is essential for normal vision. Mutations in the RPE65 gene lead to reduced or absent levels of RPE65 activity, blocking the visual cycle and resulting in impaired vision. Individuals with biallelic RPE65 mutation-associated retinal dystrophy experience progressive deterioration of vision over time. This loss of vision, often during childhood or adolescence, ultimately progresses to complete blindness. 

    Luxturna works by delivering a normal copy of the RPE65 gene directly to retinal cells. These retinal cells then produce the normal protein that converts light to an electrical signal in the retina to restore patient’s vision loss. Luxturna uses a naturally occurring adeno-associated virus, which has been modified using recombinant DNA techniques, as a vehicle to deliver the normal human RPE65 gene to the retinal cells to restore vision.

    Luxturna should be given only to patients who have viable retinal cells as determined by the treating physician(s). Treatment with Luxturna must be done separately in each eye on separate days, with at least six days between surgical procedures. It is administered via subretinal injection by a surgeon experienced in performing intraocular surgery. Patients should be treated with a short course of oral prednisone to limit the potential immune reaction to Luxturna.

    The safety and efficacy of Luxturna were established in a clinical development program with a total of 41 patients between the ages of 4 and 44 years. All participants had confirmed biallelic RPE65 mutations. The primary evidence of efficacy of Luxturna was based on a Phase 3 study with 31 participants by measuring the change from baseline to one year in a subject’s ability to navigate an obstacle course at various light levels. The group of patients that received Luxturna demonstrated significant improvements in their ability to complete the obstacle course at low light levels as compared to the control group.

    The most common adverse reactions from treatment with Luxturna included eye redness (conjunctival hyperemia), cataract, increased intraocular pressure and retinal tear.

    The FDA granted this application Priority Review and Breakthrough Therapy designations. Luxturna also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

    The sponsor is receiving a Rare Pediatric Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. A voucher can be redeemed by a sponsor at a later date to receive Priority Review of a subsequent marketing application for a different product. This is the 13th rare pediatric disease priority review voucher issued by the FDA since the program began.

    To further evaluate the long-term safety, the manufacturer plans to conduct a post-marketing observational study involving patients treated with Luxturna.

    The FDA granted approval of Luxturna to Spark Therapeutics Inc. 


  • FDA Approves Gene Therapy to Treat Patients with Rare Form of Inherited Vision Loss 05/22/2018

    FDA Approves Gene Therapy to Treat Patients with Rare Form of Inherited Vision Loss

    Read More

  • Screening for Diabetic Retinopathy 04/24/2018

    Read More

  • How Will Diabetic Retinopathy Clinical Research Network Protocol S Change Our Practice? 01/09/2018

    Read More

  • New FDA Approved Drug for Eye Swelling 12/12/2017

    New FDA Approved Drug for Eye  Swelling

    Read More

  • Surgical Management of Sub Retinal Hemorrhage 10/24/2017

    Surgical Management of Sub Retinal Hemorrhage 

    Read More

  • New Treatment for Diabetic Retinopathy 09/19/2017

    New Treatment for Diabetic Retinopathy

    Read More

  • Endophthalmitis 08/22/2017


    Read More

  • Retinal Pigment Epithelial Transplant Geographic Atrophy 05/23/2017

    For years, people were throwing away cells that could bring eyesight to the blind. These dark, blackened cells looked like spots of contamination in the petri dishes in which researchers around the world were carefully nurturing highly purified colonies of human stem cells.

    Read More

  • Retinal Prosthesis 04/25/2017

    Retinal Prosthesis

    Read More

  • Central Serous Retinopathy 01/24/2017

    Central Serous Retinopathy

    Read More

  • Retinal Vein Occlusion 11/15/2016

    Retinal Vein Occlusion

    Read More

  • Optogenetics


    Read More